4006-776-356 出国就医服务电话

免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Study Description
Brief Summary:
This phase I/II trial studies the side effects and best dose of modified immune cells called CD19-CD22 chimeric antigen receptor (CAR) T cells in treating patients with CD19 positive(+), CD22+ B-acute lymphoblastic leukemia, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma that has come back (recurrent) or does not respond to treatment (refractory). T-cells are collected from the patient and genetic materials called "chimeric antigen receptors (CAR)" are transferred to the collected T-cells. The CAR T-cells are then infused back to the patient's body. Giving CD19- CD22 CAR T cells after chemotherapy may help to control the disease.

Condition or disease Intervention/treatment Phase
CD19 Positive CD22 Positive Minimal Residual Disease Progressive Disease Recurrent B Acute Lymphoblastic Leukemia Recurrent Chronic Lymphocytic Leukemia Recurrent Non-Hodgkin Lymphoma Refractory B Acute Lymphoblastic Leukemia Refractory Chronic Lymphocytic Leukemia Refractory Non-Hodgkin Lymphoma Biological: Autologous CD19/CD22 Chimeric Antigen Receptor T-cells Drug: Cyclophosphamide Drug: Fludarabine Phase 1 Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. To determine the safety of infusion with chimeric antigen receptor T cells targeting CD19 and CD22.

II. To find the recommended phase II dose for recurrent/refractory CD19+CD22+ B cell malignancies.

SECONDARY OBJECTIVES:

I. To describe the overall response rate and complete response rate of relapsed B cell malignancies treated with CAR-T cells targeting CD19 and CD22.

II. To assess other response variables including minimal residual disease (MRD) negative remission, overall survival (OS), and event free survival (EFS).

EXPLORATORY OBJECTIVES:

I. To evaluate the immune reconstitution and persistence of CAR T cells for one year post infusion.

OUTLINE: This is a phase I, dose escalation study of autologous CD19/CD22 chimeric antigen receptor T-cells (CD19-CD22 CAR T cells) followed by a phase II study.

Patients receive standard of care cyclophosphamide intravenously (IV) over 30 minutes and fludarabine IV over 30 minutes on days -5, -4, and -3, and then receive CD19-CD22 CAR T cells IV on day 0. Patients with relapsed or persistent disease after a protocol assessment may receive a second infusion of CD19-CD22 CAR T cells.

After completion of study treatment, patients are followed up at 1, 2, 3, 6, and 12 months.

Study Design
Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Study of Dual CD19-CD22 Chimeric Antigen Receptor (CAR) T Cells in Patients With Advanced CD19+ CD22+ Lymphoid Malignancies
Estimated Study Start Date : November 30, 2020
Estimated Primary Completion Date : August 31, 2022
Estimated Study Completion Date : August 31, 2023
Arms and Interventions
Arm Intervention/treatment
Experimental: Treatment (CD19-CD22 CAR T cells)
Patients receive standard of care cyclophosphamide IV over 30 minutes and fludarabine IV over 30 minutes on days -5, -4, and -3, and then receive CD19-CD22 CAR T cells IV on day 0. Patients with relapsed or persistent disease after a protocol assessment may receive a second infusion of CD19-CD22 CAR T cells.
Biological: Autologous CD19/CD22 Chimeric Antigen Receptor T-cells
Given IV
Other Names:
  • Autologous Anti-CD19/CD22 CAR-T Cells
  • Autologous CD19/CD22 CAR T Cells
  • Autologous CD19/CD22 CAR T-cells
  • Autologous CD19/CD22 Chimeric Antigen Receptor T Cells

Drug: Cyclophosphamide
Given IV
Other Names:
  • (-)-Cyclophosphamide
  • 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate
  • Carloxan
  • Ciclofosfamida
  • Ciclofosfamide
  • Cicloxal
  • Clafen
  • Claphene
  • CP monohydrate
  • CTX
  • CYCLO-cell
  • Cycloblastin
  • Cycloblastine
  • Cyclophospham
  • Cyclophosphamid monohydrate
  • Cyclophosphamidum
  • Cyclophosphan
  • Cyclophosphane
  • Cyclophosphanum
  • Cyclostin
  • Cyclostine
  • Cytophosphan
  • Cytophosphane
  • Cytoxan
  • Fosfaseron
  • Genoxal
  • Genuxal
  • Ledoxina
  • Mitoxan
  • Neosar
  • Revimmune
  • Syklofosfamid
  • WR- 138719

Drug: Fludarabine
Given IV
Other Name: Fluradosa

Outcome Measures
Primary Outcome Measures :
  1. Optimal chimeric antigen receptor (CAR) T cell dose level [ Time Frame: Up to 30 days ]
    Dose-finding will be done using the sequentially adaptive phase I-II EffTox method.

  2. Incidence of adverse events (adverse events) [ Time Frame: Up to 30 days ]
    Toxicity is defined as a grade 3, 4, or 5 cytokine release syndrome, neurotoxicity, or National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 with onset within 30 days of cell infusion. Adverse events that are considered disease-related (not suspected of relationship to CD19-CD22 -CAR T cells) will not be considered dose-limiting toxicities. Only those AEs that occur during the first 30 days after infusion, which are suspected to be related to conditioning lymphodepletion chemotherapy regimen and/or CD19 -CD22-CAR T cells (any component of the treatment regimen), and meet the following criteria, will be used in the definition of toxicity. Hematologic toxicities will not be considered in the definition of toxicity, as pancytopenia is a common toxicity with this regimen.

  3. Efficacy in complete response (CR) or partial response [ Time Frame: Day 30 post cell infusion ]
    Efficacy is defined as the patient being alive and in complete response (CR) or partial response (PR) at day 30 post cell infusion.


Secondary Outcome Measures :
  1. Progression-free survival [ Time Frame: Up to 1 year post T-cell infusion ]
    Unadjusted distributions of the time-to-event outcomes will be estimated using the method of Kaplan and Meier and their relationship to prognostic covariates and T-cell dose level will be evaluated by Bayesian piecewise exponential survival regression.

  2. Overall survival [ Time Frame: Up to 1 year post T-cell infusion ]
    Unadjusted distributions of the time-to-event outcomes will be estimated using the method of Kaplan and Meier and their relationship to prognostic covariates and T-cell dose level will be evaluated by Bayesian piecewise exponential survival regression.


Other Outcome Measures:
  1. Immune reconstitution [ Time Frame: Up to 1 year post T-cell infusion ]
    These longitudinal values will be evaluated graphically and cross-tabulated with dose.

  2. Persistence of CAR T-cells [ Time Frame: Up to 1 year post T-cell infusion ]
    These longitudinal values will be evaluated graphically and cross-tabulated with dose.


Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   6 Months to 70 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with relapsed/refractory B-acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), or non-Hodgkin's lymphoma (NHL) treated with at least two lines of therapy, and have persistent or progressed disease including positive minimal residual disease (MRD)
  • Patients may have received last cytotoxic chemotherapy at least 3 weeks prior to lymphodepleting chemotherapy
  • Patient may continue targeted therapy until 2 weeks before initiation of lymphodepleting chemotherapy with the exception of ibrutinib
  • Disease must be CD19 and/or CD22 positive by flow cytometry or immunohistochemistry
  • Karnofsky/Lansky performance scale > 70
  • Total bilirubin less than < 1.5 mg/dL except patients with Gilbert syndrome whose total bilirubin must be < 3.0mg/dL
  • Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 X upper limit of normal (ULN)
  • Alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) =< 5.0 ULN
  • Serum creatinine (as estimated by Cockcroft Gault) >= 60 cc/min
  • Cardiac ejection fraction >= 50% without evidence of pericardiac effusion as determined by echocardiogram (ECHO) or multigated acquisition scan (MUGA), no clinical significant electrocardiogram (ECG) findings
  • No clinical significant pleural effusion and baseline oxygen saturation >= 92%
  • Absolute lymphocyte count >= 100/ul
  • Be able to sign informed consent
  • All participants who are able to have children must practice effective birth control while on study. Acceptable forms of birth control for female patients include: birth control pills, patches, or injections, intrauterine device (IUD), diaphragm with spermicide, or condom with spermicide. Acceptable forms of birth control for male patients include condom with spermicide. If female participant becomes pregnant during the study, she will be taken off this study. If male participant fathers a child while on study, he must immediately notify his doctor
  • For patients with history of allogenic stem cell transplantation

    • Should not have active acute graft-versus-host disease (GVHD) grade >= 2
    • Should not be on immunosuppressants such as tacrolimus, sirolimus, cyclosporine, mycophenolates for a minimum of a month from CD19-CD22 CAR T cell infusion
    • Should not be on more than physiologic dose of systemic steroid for adrenal insufficiency (prednisone equivalent 5mg/day)
    • Transplantation should be more than 2 months from CD19-CD22 CAR T cell infusion
    • Other cell therapy including CAR T cells, donor lymphocyte infusion, virus specific T cells, natural killer (NK) cells, etc should have 6 weeks of wash-out period from the CD19-CD22 CAR T cell infusion
  • For patients with history of central nervous system (CNS) disease, CNS disease must be treated prior to enrollment
  • For patients with prior treatment history of cell therapy such as other CAR T cells or CAR NK cells or NK cells, cell therapy should have a 6 weeks of wash-out period from CD19-CD22 CAR T cell infusion
  • Be able to consent long-term follow-up protocol PA17-0483

Exclusion Criteria:

  • Positive beta-human chorionic gonadotropin (hCG) in female of child bearing potential defined as not postmenopausal for 24 months or no previous surgical sterilization or lactating females
  • Known positive serology for human immunodeficiency virus (HIV)
  • Presence of active grade 3 or greater toxicity from the previous treatment
  • Presence of active fungal, bacterial, viral, or other infection requiring IV antibiotics for management
  • Presence of active neurologic disorders
  • Concomitant use of other investigational agents
  • Current use of corticosteroid more than physiological dose for adrenal insufficiency (prednisone equivalent at a dose higher than 10 mg/day)
  • Presence of active CNS disease
Contacts and Locations

Contacts
Layout table for location contacts
Contact: Jin Seon Im 832-750-1502 jim@mdanderson.org

Locations
Layout table for location information
United States, Texas
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Contact: Jin Seon Im    832-750-1502    jim@mdanderson.org   
Principal Investigator: Jin Seon Im         
Sponsors and Collaborators
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Jin S Im M.D. Anderson Cancer Center
Tracking Information
First Submitted Date  ICMJE July 19, 2019
First Posted Date  ICMJE July 23, 2019
Last Update Posted Date June 19, 2020
Estimated Study Start Date  ICMJE November 30, 2020
Estimated Primary Completion Date August 31, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 19, 2019)
  • Optimal chimeric antigen receptor (CAR) T cell dose level [ Time Frame: Up to 30 days ]
    Dose-finding will be done using the sequentially adaptive phase I-II EffTox method.
  • Incidence of adverse events (adverse events) [ Time Frame: Up to 30 days ]
    Toxicity is defined as a grade 3, 4, or 5 cytokine release syndrome, neurotoxicity, or National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 with onset within 30 days of cell infusion. Adverse events that are considered disease-related (not suspected of relationship to CD19-CD22 -CAR T cells) will not be considered dose-limiting toxicities. Only those AEs that occur during the first 30 days after infusion, which are suspected to be related to conditioning lymphodepletion chemotherapy regimen and/or CD19 -CD22-CAR T cells (any component of the treatment regimen), and meet the following criteria, will be used in the definition of toxicity. Hematologic toxicities will not be considered in the definition of toxicity, as pancytopenia is a common toxicity with this regimen.
  • Efficacy in complete response (CR) or partial response [ Time Frame: Day 30 post cell infusion ]
    Efficacy is defined as the patient being alive and in complete response (CR) or partial response (PR) at day 30 post cell infusion.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 19, 2019)
  • Progression-free survival [ Time Frame: Up to 1 year post T-cell infusion ]
    Unadjusted distributions of the time-to-event outcomes will be estimated using the method of Kaplan and Meier and their relationship to prognostic covariates and T-cell dose level will be evaluated by Bayesian piecewise exponential survival regression.
  • Overall survival [ Time Frame: Up to 1 year post T-cell infusion ]
    Unadjusted distributions of the time-to-event outcomes will be estimated using the method of Kaplan and Meier and their relationship to prognostic covariates and T-cell dose level will be evaluated by Bayesian piecewise exponential survival regression.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: July 19, 2019)
  • Immune reconstitution [ Time Frame: Up to 1 year post T-cell infusion ]
    These longitudinal values will be evaluated graphically and cross-tabulated with dose.
  • Persistence of CAR T-cells [ Time Frame: Up to 1 year post T-cell infusion ]
    These longitudinal values will be evaluated graphically and cross-tabulated with dose.
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
Official Title  ICMJE Phase I/II Study of Dual CD19-CD22 Chimeric Antigen Receptor (CAR) T Cells in Patients With Advanced CD19+ CD22+ Lymphoid Malignancies
Brief Summary This phase I/II trial studies the side effects and best dose of modified immune cells called CD19-CD22 chimeric antigen receptor (CAR) T cells in treating patients with CD19 positive(+), CD22+ B-acute lymphoblastic leukemia, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma that has come back (recurrent) or does not respond to treatment (refractory). T-cells are collected from the patient and genetic materials called "chimeric antigen receptors (CAR)" are transferred to the collected T-cells. The CAR T-cells are then infused back to the patient's body. Giving CD19- CD22 CAR T cells after chemotherapy may help to control the disease.
Detailed Description

PRIMARY OBJECTIVES:

I. To determine the safety of infusion with chimeric antigen receptor T cells targeting CD19 and CD22.

II. To find the recommended phase II dose for recurrent/refractory CD19+CD22+ B cell malignancies.

SECONDARY OBJECTIVES:

I. To describe the overall response rate and complete response rate of relapsed B cell malignancies treated with CAR-T cells targeting CD19 and CD22.

II. To assess other response variables including minimal residual disease (MRD) negative remission, overall survival (OS), and event free survival (EFS).

EXPLORATORY OBJECTIVES:

I. To evaluate the immune reconstitution and persistence of CAR T cells for one year post infusion.

OUTLINE: This is a phase I, dose escalation study of autologous CD19/CD22 chimeric antigen receptor T-cells (CD19-CD22 CAR T cells) followed by a phase II study.

Patients receive standard of care cyclophosphamide intravenously (IV) over 30 minutes and fludarabine IV over 30 minutes on days -5, -4, and -3, and then receive CD19-CD22 CAR T cells IV on day 0. Patients with relapsed or persistent disease after a protocol assessment may receive a second infusion of CD19-CD22 CAR T cells.

After completion of study treatment, patients are followed up at 1, 2, 3, 6, and 12 months.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • CD19 Positive
  • CD22 Positive
  • Minimal Residual Disease
  • Progressive Disease
  • Recurrent B Acute Lymphoblastic Leukemia
  • Recurrent Chronic Lymphocytic Leukemia
  • Recurrent Non-Hodgkin Lymphoma
  • Refractory B Acute Lymphoblastic Leukemia
  • Refractory Chronic Lymphocytic Leukemia
  • Refractory Non-Hodgkin Lymphoma
Intervention  ICMJE
  • Biological: Autologous CD19/CD22 Chimeric Antigen Receptor T-cells
    Given IV
    Other Names:
    • Autologous Anti-CD19/CD22 CAR-T Cells
    • Autologous CD19/CD22 CAR T Cells
    • Autologous CD19/CD22 CAR T-cells
    • Autologous CD19/CD22 Chimeric Antigen Receptor T Cells
  • Drug: Cyclophosphamide
    Given IV
    Other Names:
    • (-)-Cyclophosphamide
    • 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate
    • Carloxan
    • Ciclofosfamida
    • Ciclofosfamide
    • Cicloxal
    • Clafen
    • Claphene
    • CP monohydrate
    • CTX
    • CYCLO-cell
    • Cycloblastin
    • Cycloblastine
    • Cyclophospham
    • Cyclophosphamid monohydrate
    • Cyclophosphamidum
    • Cyclophosphan
    • Cyclophosphane
    • Cyclophosphanum
    • Cyclostin
    • Cyclostine
    • Cytophosphan
    • Cytophosphane
    • Cytoxan
    • Fosfaseron
    • Genoxal
    • Genuxal
    • Ledoxina
    • Mitoxan
    • Neosar
    • Revimmune
    • Syklofosfamid
    • WR- 138719
  • Drug: Fludarabine
    Given IV
    Other Name: Fluradosa
Study Arms  ICMJE Experimental: Treatment (CD19-CD22 CAR T cells)
Patients receive standard of care cyclophosphamide IV over 30 minutes and fludarabine IV over 30 minutes on days -5, -4, and -3, and then receive CD19-CD22 CAR T cells IV on day 0. Patients with relapsed or persistent disease after a protocol assessment may receive a second infusion of CD19-CD22 CAR T cells.
Interventions:
  • Biological: Autologous CD19/CD22 Chimeric Antigen Receptor T-cells
  • Drug: Cyclophosphamide
  • Drug: Fludarabine
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: July 19, 2019)
30
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE August 31, 2023
Estimated Primary Completion Date August 31, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients with relapsed/refractory B-acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), or non-Hodgkin's lymphoma (NHL) treated with at least two lines of therapy, and have persistent or progressed disease including positive minimal residual disease (MRD)
  • Patients may have received last cytotoxic chemotherapy at least 3 weeks prior to lymphodepleting chemotherapy
  • Patient may continue targeted therapy until 2 weeks before initiation of lymphodepleting chemotherapy with the exception of ibrutinib
  • Disease must be CD19 and/or CD22 positive by flow cytometry or immunohistochemistry
  • Karnofsky/Lansky performance scale > 70
  • Total bilirubin less than < 1.5 mg/dL except patients with Gilbert syndrome whose total bilirubin must be < 3.0mg/dL
  • Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 X upper limit of normal (ULN)
  • Alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) =< 5.0 ULN
  • Serum creatinine (as estimated by Cockcroft Gault) >= 60 cc/min
  • Cardiac ejection fraction >= 50% without evidence of pericardiac effusion as determined by echocardiogram (ECHO) or multigated acquisition scan (MUGA), no clinical significant electrocardiogram (ECG) findings
  • No clinical significant pleural effusion and baseline oxygen saturation >= 92%
  • Absolute lymphocyte count >= 100/ul
  • Be able to sign informed consent
  • All participants who are able to have children must practice effective birth control while on study. Acceptable forms of birth control for female patients include: birth control pills, patches, or injections, intrauterine device (IUD), diaphragm with spermicide, or condom with spermicide. Acceptable forms of birth control for male patients include condom with spermicide. If female participant becomes pregnant during the study, she will be taken off this study. If male participant fathers a child while on study, he must immediately notify his doctor
  • For patients with history of allogenic stem cell transplantation

    • Should not have active acute graft-versus-host disease (GVHD) grade >= 2
    • Should not be on immunosuppressants such as tacrolimus, sirolimus, cyclosporine, mycophenolates for a minimum of a month from CD19-CD22 CAR T cell infusion
    • Should not be on more than physiologic dose of systemic steroid for adrenal insufficiency (prednisone equivalent 5mg/day)
    • Transplantation should be more than 2 months from CD19-CD22 CAR T cell infusion
    • Other cell therapy including CAR T cells, donor lymphocyte infusion, virus specific T cells, natural killer (NK) cells, etc should have 6 weeks of wash-out period from the CD19-CD22 CAR T cell infusion
  • For patients with history of central nervous system (CNS) disease, CNS disease must be treated prior to enrollment
  • For patients with prior treatment history of cell therapy such as other CAR T cells or CAR NK cells or NK cells, cell therapy should have a 6 weeks of wash-out period from CD19-CD22 CAR T cell infusion
  • Be able to consent long-term follow-up protocol PA17-0483

Exclusion Criteria:

  • Positive beta-human chorionic gonadotropin (hCG) in female of child bearing potential defined as not postmenopausal for 24 months or no previous surgical sterilization or lactating females
  • Known positive serology for human immunodeficiency virus (HIV)
  • Presence of active grade 3 or greater toxicity from the previous treatment
  • Presence of active fungal, bacterial, viral, or other infection requiring IV antibiotics for management
  • Presence of active neurologic disorders
  • Concomitant use of other investigational agents
  • Current use of corticosteroid more than physiological dose for adrenal insufficiency (prednisone equivalent at a dose higher than 10 mg/day)
  • Presence of active CNS disease
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 6 Months to 70 Years   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Jin Seon Im 832-750-1502 jim@mdanderson.org
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04029038
Other Study ID Numbers  ICMJE 2019-0042
NCI-2019-04229 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
2019-0042 ( Other Identifier: M D Anderson Cancer Center )
P30CA016672 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party M.D. Anderson Cancer Center
Study Sponsor  ICMJE M.D. Anderson Cancer Center
Collaborators  ICMJE National Cancer Institute (NCI)
Investigators  ICMJE
Principal Investigator: Jin S Im M.D. Anderson Cancer Center
PRS Account M.D. Anderson Cancer Center
Verification Date June 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

治疗医院